AllDocs -> cancers

August 16, 2004 Vaccine plus drugs improves brain cancer survival Clinical Cancer Research: http://www.reutershealth.com/ NEW YORK (Reuters Health) - Treating patients who have glioblastoma multiforme, a lethal type of brain tumor, with an experimental vaccine seems to sensitize the tumor to subsequent chemotherapy, according to a study by researchers at Cedars-Sinai Medical Center in Los Angeles. In the study, published in Clinical Cancer Research, patients with these brain tumors who were treated with both a cancer vaccine and chemotherapy survived longer and exhibited delayed tumor progression compared with those treated with either therapy alone. "This is the strongest effect of any therapy on brain tumors we've seen so far," lead investigator Dr. Christopher J. Wheeler told Reuters Health. The patients, ages 32 to 78 years old, underwent surgery and radiation therapy. ...

brain cancer Brain Cancer By Cara Klingaman Significance The brain is the center of thoughts, emotions, memory and speech. Brain also control muscle movements and interpretation of sensory information (sight, sound, touch, taste, pain etc) Significance Tumors can effect any part of the brain and depending on what part(s) of the brain it affects can have a number of symptoms. Seizures Difficulty with language Mood changes Change of personality Changes in vision, hearing, and sensation. Difficulty with muscle movement Difficulty with coordination control Background Estimated 18,400 primary malignant brain tumors will be diagnosed in 2004 —10,540 in men & 7,860 in women. Approximately 12,690 people will die from these tumors in 2004. ...

Media Contact: Sandra Van Telephone: 1-800-880-2397 E-mail: sandy@vancommunications.com Oct. 1, 2003 – FOR IMMEDIATE RELEASE POSSIBLE BRAIN CANCER -AIR POLLUTION LINK TO BE STUDIED By Internationally Renowned Neurosurgeon and AQMD Foundation LOS ANGELES, CA (Oct. 1, 2003 – The Brain Tumor and Air Pollution Foundation today announced the beginning of a research project led by an internationally renowned neurosurgeon at Cedars-Sinai Medical Center to explore a possible link between brain cancer and air pollution. The study will be led by Keith Black, M.D., director of the Cedars-Sinai Maxine Dunitz Neurosurgical Institute and Division of Neurosurgery in Los Angeles. The Brain Tumor foundation recently awarded $559,250 to the research project, with funding from the South Coast Air Quality Management District (AQMD). The Cedars-Sinai investigation will examine biochemical and ...

X. Statistical Tables 88 Oregon State Cancer Registry Average Percent Average Percent Invasive Age Annual Malignant Age Annual Cases Adjusted Trend Deaths Adjusted Trend OREGON COUNTY INCIDENCE MORTALITY Per Year 1 Rate (APC) Per Year Rate (APC) 1996 - 2000 Rates are per 100,000 and age-adjusted to the 2000 U.S. (5-year groups) standard. * Trend is statistically stable. 1 Counts may not match state tables due to cases in unknown counties. ^ Rate not calculated due to instability of small numbers. APC = Average Annual Percent Change DATA Table 3b: Malignant Brain Cancer State of Oregon 229 6.9 -3.4 186 5.5 -2.9 ...

All-Ireland cancer statistics 1994-96 90 Brain 21. MALIGNANT CANCER OF THE BRAIN (summary) ICD-O.2 C71 ICD-10 C71 ICD-9 191 Figures presented are for primary, malignant tumours. Cancer of the meninges (ICD-10 C70) or of the central nervous system (C72) other than the brain itself are excluded, except where comparison is made with EU figures. Key facts • Average of 315 new cases per year, 1994-96: 148 in females, 200 in males. • Average of 297 deaths per year: 130 in females, 167 in males. • Age-standardised incidence and mortality rates about 50% higher in males than females. • 11th most common site for cancer incidence in males, 15th in females. • 8th most common cause of cancer deaths in females, 9th in males. • Median age at diagnosis 57 years for females and 55 years for males (lower than for cancers ...

APPENDIX A SECTION 1. SHORT TITLE. This Act may be cited as the `Benign Brain Tumor Cancer Registries Amendment Act'. SEC. 2. NATIONAL PROGRAM OF CANCER REGISTRIES; BENIGN BRAIN - RELATED TUMORS AS ADDITIONAL CATEGORY OF DATA COLLECTED. (a) IN GENERAL- Section 399B of the Public Health Service Act (42 U.S.C. 280e), as redesignated by section 502(2)(A) of Public Law 106-310 (114 Stat. 1115), is amended in subsection (a)-- (1) by redesignating paragraphs (1) through (5) as subparagraphs (A) through (E), respectively, and indenting appropriately; (2) by striking `(a) IN GENERAL- The Secretary' and inserting the following: `(a) IN GENERAL- `(1) STATEWIDE CANCER REGISTRIES- The Secretary'; (3) in the matter preceding subparagraph (A) (as so redesignated), by striking `population-based' and all that follows through `data' and inserting the following: `population-based, ...

K S Biomedix Holdings PLC ( LS:KSB ) Licenses TransMID Brain Cancer Product To Sosei Co., Ltd. In $25 Million Japanese Deal GUILDFORD, England and LONDON and TOKYO, May 27 /PRNewswire-FirstCall/ - - KS Biomedix Holdings plc ("KSB") (LSE: KSB) and Sosei Co. Ltd. ("Sosei") announce that KSB has appointed Sosei as the Japanese licensee for its TransMID(TM) product in a $25 million licensing deal. TransMID(TM) is a novel biopharmaceutical product in development for the treatment of recurrent high grade glioma, a terminal brain cancer for which there is no known cure. This deal is the first TransMID(TM) licensing deal agreed by KSB since it acquired the technology in July 2001. Japan constitutes around 20% of the total worldwide market for glioma treatments and is the second largest single market in the world after the USA. Under the terms of the deal, KSB will receive an upfront payment together ...

Telephone 13 11 20 for cancer information and support A GUIDE FOR PEOPLE WITH THESE TUMOURS, THEIR FAMILIES AND FRIENDS A GUIDE FOR PEOPLE WITH THESE TUMOURS, THEIR FAMILIES AND FRIENDS Brain Spinal Cord Brain and and Spinal Cord Tumours Tumours Page 2 Brain and Spinal Cord Tumours First published (as Brain Cancer ) 1995 This edition December 2003 Acknowledgments The Cancer Council thanks everyone who contributed to the development and revision of this booklet. Illustration on page 7 by Con Stamatis. The Cancer Council Victoria is an independent, volunteer-based charity whose mission is to lead, coordinate, implement and evaluate action to minimise the human cost of cancer for all Victorians. Many ...

brain cancer Malignant Brain Cancer Trial Category: Glioblastoma Multiforme (GBM) ? Newly Diagnosed Trial: Phase II Trial of Investigational Drug Poly-ICLC with Concurrent Radiation Therapy Post Surgical Resection ? NABTC 01-05 Sponsor: North American Brain Tumor Consortium (NABTC) Available: UCSF and UCLA Principal Investigator Contacts: UCSF Dr. Michael Prados 415-353-2966 pradosm@neurosurg.ucsf.edu UCLA Dr. Timothy Cloughesy 310-825-5321 tcloughe@ucla.edu Background: Poly-ICLC is an investigational ...

TABLE III - 41 Summary of Resident Brain Cancer Deaths by Year Douglas County, Nebraska 1987-2002 2002# 2001# 2000# 1999# 1998 1997 1996 1995 1994 1993 1992 1991 1990 1989 1988 1987 Deaths 15 23 20 15 25 21 18 25 27 23 27 16 19 17 31 16 Rates per 100,000 Population*: Crude Rate 3.2 4.9 4.3 3.3 5.5 4.7 4.0 5.7 6.2 5.3 6.3 3.8 4.6 4.1 7.6 3.9 2000 Age-adjusted Rate 3.5 5.2 4.7 3.5 6.1 5.1 4.3 6.5 6.8 5.6 7.2 4.0 4.8 4.7 8.5 4.6 Sex: Male 8 10 10 7 11 13 12 15 9 14 9 9 11 10 11 7 Female 7 13 10 ...

Oregon’s County Data Incidence Mortality Invasive Adjusted Invasive Adjusted Age Age * Counts may not match state tables due to cases in unknown counties. ^ Rate not calculated due to instability of small numbers. Rates are per 100,000 and age-adjusted to the 2000 U.S. standard. Count* Rate Deaths Rate 1996 - 1999 88 Cancer in Oregon, 1999 X. Statistical Tables 88 Table 3b: Malignant Brain Cancer STATE 898 6.8 741 5.6 Baker 6 ^ 7 ^ Benton 18 6.6 14 5.5 Clackamas 90 7.0 67 5.3 Clatsop 8 ^ 5 ^ Columbia 13 7.7 7 ^ Coos 17 5.6 17 5.1 Crook 3 ^ 3 ^ Curry 9 ^ 8 ^ Deschutes ...

statistics Brain Cancer Source: PENN State - Graduate Student Research Statistics: PA Department of health, Bureau of Health Statistics ( 2001, August) Analysis of cancer incidence in PA counties 1994-1998 1999 Brain Cancer Statistics (Ages 15 and above) Tri County Area Cases per 100,000 Montgomery County 73 10.08 Berks County 35 9.77 Chester County 22 5.12 1999 (Ages 15 and above) Montgomery County has the HIGHEST RATE of brain cancer by a large margin compared to: U.S., PA, and Tioga County in PA ( a less polluted county for comparison) Brain Cancer in Montgomery County (1995 to 1999) almost DOUBLED in only 5 years Montgomery County Brain Cancer 1995 5.80 per 100,000 1999 10.08 per 100,000 1999 Brain Cancer Statistics - Pottstown Brain Cancer Rate per 100,000 in Pottstown - 9.25 ¯ This is SIGNIFICANTLY ...

Saturday, August 10, 2002 NanoInvestorNews - Advectus Life Sciences Inc. update - Pre-clinical brain cancer collaboration Page: 1 http://www.nanoinvestornews.com/modules.php?name=AvantGo&file=print&sid=625 Advectus Life Sciences Inc. update - Pre-clinical brain cancer collaboration Date: Wednesday, August 07 @ 13:22:32 EDT Topic: PRs AVX:TSX VENTURE WKN. 693000 BERLIN AVXSF. NASD VANCOUVER, Aug 07, 2002 (Canada NewsWire via COMTEX) -- Advectus Life Sciences Inc. [ profile ] in collaboration with the University of North Carolina at Chapel Hill (News Release No. 02 - 11 May 30, 2002) has completed the first phase of an in vitro study to determine the efficacy and sensitivity of its patented nanoparticle based technology (Nanocure(TM) formulation P80DOX-NP) on eight metastatic malignancies. There was an excellent dose response curve for all cancer cell lines tested with some ...

We look forward to seeing you at our seminars ADVECTUS LIFE SCIENCES INC. - PRE-CLINICAL BRAIN CANCER TESTING UNDERWAY July 1, 2002 - Canada Newswire - Investments, Health AVX: TSX VENTURE WKN. 693000 BERLIN AVXSF. NASD VANCOUVER, July 1 /CNW/ - Advectus Life Sciences Inc. announced today that pre-clinical testing of its patented nanoparticle based technology (Nanocure(TM)) has commenced at the University of North Carolina Brain Tumor Center. This series of studies will test the Nanocure(TM) formulation P80DOX- NP on rodent brain metastases arising from lung carcinoma (2), breast carcinoma, melanoma, renal cell carcinoma, and colon carcinoma. P80DOX-NP is a novel method for the delivery of doxorubicin across the blood- brain barrier. The above study design will be a randomized, placebo- controlled study measuring survival as a surrogate ...

1 Brain Cancer and Magnetic Resonance Spectroscopy Jeffry R. Alger, PhD Department of Radiological Sciences Jonsson Comprehensive Cancer Center Brain Research Institute Ahmanson-Lovelace Brain Mapping Center University of California, Los Angeles I. Introduction II. MRS fundamentals in relation to brain cancer III. The MRS appearance of brain tumors IV. Clinical uses of MRS for brain tumor management V. Summary VI. Glossary VII. Bibliography I. Introduction Brain cancer has been studied with Magnetic Resonance Spectroscopy (MRS) for approximately the past ten years. This research is now leading to the regular use of MRS for the routine clinical evaluation of brain cancer patients. This article will summarize the present state of knowledge related to MRS and brain cancer and illustrate ...

6 C L E V E L A N D C L I N I C T A U S S I G C A N C E R C E N T E R T HE C LEVELAND C LINIC T AUSSIG C ANCER C ENTER is participating in an international, pivotal Phase III clinical study combining Xcytrin (motexafin gadolinium) and whole brain radiation therapy (WBRT) for non-small cell lung cancer patients with brain metastases. Clinic radiation oncologist John Suh, M.D., is an investigator for this multinational trial. “The SMART trial is designed to assess the impact of whole brain radiation therapy on neuro- cognitive function. Although the main goal is to achieve extended control in brain metastases patients, quality of life issues ...

Berkshire Priorities Committee Policy Statement 39 Temozolomide for Brain Cancer Date of Issue August 2001 Review Date March 2004 Malignant glioma is the most common form of primary brain cancer in England and Wales (about 3,500 patients each year) but accounts for less than 1% of all cancers. In Berkshire this is approximately 10-12 patients; patients currently receive supportive care with steroids and or anticonvulsants. The National Institute of Clinical Excellence (NICE) reviewed the one RCT available comparing Temozolomide with procarbazine (225 patients); progression free survival at six months was 21% Vs 8%. However, the median survival advantage was six weeks and not deemed statistically significant. The cost effectiveness of Temozolomide was not considered due to the limited clinical effectiveness evidence available. NICE recommends ...

188 N ORTHERN C ALIFORNIA C ANCER C ENTER , Cancer Incidence and Mortality in the Greater San Francisco Bay Area Brain and Other Nervous System Cancer TABLE 1. Brain and Other Nervous System Cancer . Annual Death Counts, Age-Adjusted Mortality Rates per 100,000 Population, a and 95% Confidence Intervals (CI), by Sex and Race/Ethnicity, 1988-2000, Greater San Francisco Bay Area b TOTAL MALES FEMALES Year Count Rate 95% CI Count Rate 95% CI Count Rate 95% CI ALL RACES 1988-1993 c 1,405 4.4 4.2-4.7 792 5.5 5.1-5.9 613 3.5 3.3-3.8 1994 230 4.1 3.5-4.6 133 5.0 4.2-6.0 97 ...